Hospital infection therapeutics market eyes 5.27% CAGR growth until 2028

It is expected to grow by $3.46b amidst the increasing prevalence of HAIs within the forecast period.

The global market for hospital infection therapeutics is projected to grow by $3.46b until 2028 at a compound annual growth rate (CAGR) of 5.27%.

A report by Technavio revealed that the market is driven by the rising prevalence of hospital-acquired infections (HAIs) which could lead to health significant health risks and financial burdens to patients and healthcare systems.

“Therapeutics is expected to grow steadily due to the rising demand for effective solutions to combat HAIs, as well as advancements in technology and research,” Technavio said.

Urbanisation, construct technology, and engineering are considered crucial in creating infection-resistant environments, with products such as antimicrobial coatings and disinfectants playing an essential role in the market.

Moreover, renewable and sustainable technologies like UV light disinfection, are gaining popularity due to their effectiveness against a wide range of microorganisms.

The market is also anticipated to expand amidst the growing presence of chronic diseases and the increasing number of patient visits to hospitals and is influenced by factors such as the ageing population and rising healthcare expenditures.

“The ageing population, particularly in Japan, the UK, the US, and Germany, is more susceptible to infections and is expected to increase by 8% to 10% by 2030, driving the demand for blood culture tests and market growth,” the report added.